



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

HTLV 2024 List of Posters

Posters presented in poster session 1: Monday 3rd June 17:00 – 19:00

Posters presented in poster session 2: Tuesday 4th June 17:10 – 19:00

Diagnosis

P001

A novel high-performance rapid screening test for the detection of total HTLV-I and HTLV-II antibodies in HTLV-I/II infected patients

Haris Ong

P002

Radiculopathy as a neurologic complication of HTLV-1

Reza Boostani

P003

ATL risk assessment using RAISING, a novel clonality analysis method for HTLV-1-infected cell

Tomoo Sato

P004

Study on application of whole blood samples to novel lateral-flow immunochromatographic HTLV-1/2 antibody testing

Madoka Kuramitsu

P005

Distribution of proviral DNA of bovine leukemia virus in blood and different tissues in asymptomatic BLV-infected cattle

Marzena Rola-Łuszczak

P006

Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma

Jun-ichirou Yasunaga

P007

Timing of loss of maternal antibodies in infants born to mothers living with Human T-cell Lymphotropic Virus Type 1

Ingrid Burkhardt

P008

Three decades of experience in the diagnosis of HTLV-1/2 in Argentina

Nicolás Ducasa



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P009

Longitudinally extensive transverse myelitis associated with Human T-lymphotropic virus 1: case report

Flávia Esper Dahy

P011

Laboratory follow-up of HTLV-1 exposed babies: A systematic review of the literature

Carolina Rosadas

P012

A strategy for HTLV-1/2 screening based on ELISA test on gingival crevicular fluid in endemic areas

Marzia Puccioni-Sohler

P101

Prevalence of HTLV-1/2 indeterminate Western Blot profile in blood donors and pregnant women

Blanka Patho

P128

HTLV-1 proviral load quantification in whole blood, buffy coat and peripheral blood mononuclear cells: a comparative study

Carolina Rosadas

P130

Experience report on the process of implementing screening and confirmatory tests for htlv infection at the central public health laboratory of the state of paraíba (lacen-pb)

Aldenair Torres

Epidemiology

P013

Screening for HTLV-1 infection should be expanded everywhere

Vicente Soriano

P014

Frequency and risk factors for HTLV and coinfections in blood donors in the state of Bahia, Brazil

Luisa Meireles

P015

Prevalence of HTLV infection in pregnant women in Central and South America: a systematic review and meta-analysis

Vicente Soriano



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P016

Coexistent Adult T-cell Leukemia/Lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a Peruvian cohort of people with HTLV-1 infection: A case series

Eduardo Gotuzzo

P017

Epidemiological and clinical features of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma (ATLL): A 30-years experience in Peru

Eduardo Gotuzzo

P018

HTLV-1 surveillance in Spain, a non-endemic country

Mikel Blanco-Otaegui

P019

HTLV screening of blood donations in Spain

Carmen de Mendoza

P020

New insight into Bovine leukemia virus genotype G12 circulating in East Kazakhstan

Marzena Rola-Łuszczak

P022

Anti-HTLV screening of blood donors in the UK: identifying asymptomatic HTLV-positive donors to improve access to specialist care

Katy Davison

P023

UK's HTLV National Register cohort - what have we learned about the health and well-being of an asymptomatic cohort in twenty years of follow-up?

Katy Davison

P024

Molecular epidemiology of the T-Cell Lymphotropic Virus Type 1 (HTLV-1) in infected people from the state of Maranhão

Vinicios Arraes

P025

Molecular epidemiology and genetic variability of HTLV-1 in Central Africa. Analysis of 42 complete sequences from 12 countries

Antoine Gessain

P131

Navigation for Intensive and Optimized Surveillance – NAVIO

Luiz Carlos Junior Alcantara



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

Host pathogen interaction

P027

Functional comparison of Tax from HTLV-1 endemic genotypes using a multi-omics approach
Thomas Duchateau

P028

Assessing HTLV-Host Interactions with Alphafold2: Which transcription factors will Hbz bind to and why?

Isobel Mitic

P029

The HTLV-1c genomic landscape reveals host-virus interactions in a humanised mouse model of infection

Natasha Jansz

P030

A new cell line for high-throughput Human T-cell leukemia virus specific antibody-dependent cellular cytotoxicity (ADCC) assay development and optimization

Cynthia Pise-Masison

P032

Function on N6-methyladenosine (m6A) modification in HTLV-1 infected cells

Rei Higa

P034

HBZ and Tax influence on regulatory T-cell response and inflammatory profile in HTLV-1-associated myelopathy/tropical spastic paraparesis

Ana Carolina Marinho Monteiro Lima

P035

Defining a role for actin cytoskeleton regulation in HTLV-1 particle assembly and infectious spread

Gloria Baxter

P036

Simultaneous single-cell sequencing of the provirus, integration site & transcriptome

Jocelyn Turpin

P037

Decoding bovine leukemia virus cell-to-cell transmission: exploring the role of tunneling nanotubes

Natalia Olivero-Deibe

P038

HTLV-1 Associated myelopathy (HAM) incidence in asymptomatic carriers and intermediate syndrome (IS) patients in the 5 years follow-up in a Brazilian Cohort.

Augusto Penalva de Oliveira



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

Infection/coinfection

P040

Impaired Humoral Response Following COVID-19 Vaccination in HTLV-1 Carriers

Atae Utsunomiya

P041

Fresh human breast milk prevents chronically HTLV-1 infected T cells from cell death in an acidic environment of the stomach and enhances the release of viral particles

Franziska Wittdorf

P042

Cellular and humoral immunological profile of human T-lymphotropic virus type I in a pediatric case series

Juan Rojas

P043

Viral clonal landscape and tumor progression: lessons from tumor-resistant sheep in the BLV leukemia model

Anne-Sophie Reuter

P044

Establishment of a novel human T-cell leukemia virus type 1 infection model using with cell-free virus

Koh Nagata

P046

HTLV HIV-1 co-infection in the United Kingdom: a descriptive analysis

Rahal Fernando

Infectivity

P047

Characterizing the intercellular transfer of the mobile HTLV-1 accessory protein p8

Florian Simon

P048

Simultaneous depletion of NK, CD8+ and monocytes enhances acute but not chronic HTLV-1 infection of macaques

Anna Gutowska

P050

HTLV-1 infection in lung alveolar epithelial cells using cell-based electrical impedance technology

Clément Heymann



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

Inflammation

P051

Which interferon γ release assays, T-SPOT.TB test or QuantiFERON-TB, is more usefulness as a screening test for latent tuberculosis infection in HTLV-1-positive patients with rheumatic disease?

Masatoshi Kimura

P052

Characterizing pathological HTLV-1-infected T cell clones in HAM/TSP

Satoshi Nozuma

P053

Integrated single cell analysis of HTLV-1 specific CD8 T cells in peripheral blood and cerebrospinal fluid from HAM/TSP patients

Kenji Sugata

P055

Elevated regulatory T Cell levels in patients with HTLV-associated diseases in Stockholm cohort

Anna-Karin Svensson

P056

Proliferation assay using CarboxyFluorescein Succinimidyl Ester (CFSE) validated in different outcomes of the HTLV-1-infection in Sao Paulo, Brazil

Tatiane Assone

P057

Leptomeningeal Gadolinium Enhancement in HAM/TSP versus Multiple Sclerosis: Brain Imaging and Immune Correlations

Yoshimi Akahata

P058

High levels of CXCL10 in plasma of asymptomatic people living with HTLV-1 with high risk of developing HAM

Carolina Rosadas

P059

Gene expression of cytosolic sensors (STING and GAS) in patients with HTLV-1 and associated diseases

Aline Lima

P060

Comparison of phenotypes and functions in HTLV-1 Tax-specific cytotoxic T-lymphocytes between HAM patients and carriers

Ryuji Kubota



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

Oncology

P061

Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations

Kosuke Mochida

P062

Peginterferon alfa-2a (PEG-IFN) and Bictegravir/emtricitabine/tenofovir alafenamide alone or in combination in North American Adult T-Cell leukemia lymphoma (NA-ATLL)

R.Alejandro Sica

P063

Venetoclax shows promising activity in relapsed/refractory North American ATLL (R/R NA-ATLL) but responses were not durable in TP53 mutant cases

R. Alejandro Sica

P064

Capicua (CIC) mutations are a negative prognostic marker in Adult T-cell leukemia/lymphoma (ATLL) patients

Emma Cordover

P065

Clonality evaluation using RISING method for patients with Adult T-cell Leukemia relapsed after complete remission

Nariyoshi Matsumoto

P066

Spatio-temporal variation of HTLV-1 bZIP factor protein is associated with leukemogenesis of HTLV-1

Wenyi Zhang

P067

IRF4 and PRKCB as therapeutic TCR targets in ATLL

Lee Ratner

P068

Characterizing the role of PRMT5 in HTLV-1 disease pathogenesis

Kyle Erzen

P070

Elevated levels of soluble form of immune checkpoint in patients with aggressive adult T-cell leukemia-lymphoma

Shigeo Fuji

P071

Mycosis fungoides associated to HTLV-1 infection in a Peruvian cohort: a case series

Eduardo Gotuzzo



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P072

Killing of HTLV-1-transformed cells through manipulation of redox balance

Arezoo Darbandi

P076

Retrospective Study of Mogamulizumab in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma

Maya Srinivasan

P077

Barriers to Allogeneic Stem Cell Transplantation in Adult T Cell Lymphoma/Leukemia in the United States – Analysis of Reasons ATLL Patients on the Bv-CHEP Study Did Not Proceed With Transplant

Maya Srinivasan

P079

The use of anti-retrovirals post allogeneic stem cell transplantation to achieve a functional HTLV-1 cure: The UK experience

Craig Lennie

Pathogenesis

P081

HTLV-1 infected T-cells cause bone loss via small extracellular vesicles

Deborah Veis

P082

Dysregulation of the tumor suppressor Menin and its target Bach2 in HTLV-1 infection

Mineki Saito

P083

The establishment of a transgenic mouse system to analyse HTLV-1-driven CD4+ T cell immortalisation mechanism

M Ishrat Jahan

P084

The presence and possible role of virus-host chimeric transcripts in adult T-cell leukemia-lymphoma

Hiroo Katsuya

P085

Genetic diversity of β -retroviruses causing respiratory cancers in small ruminants

Jocelyn Turpin

P086

Increased spinal cord atrophy and lower brain lesion load differentiate HAM/TSP from multiple sclerosis

Govind Nair



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P087

HTLV-2 and bacterial pneumonia in injection drug users

Edward Murphy

P088

Role of RNA binding proteins in Human T Cell Leukemia Virus Type1 RNA stability and gene expression in latently infected CD4 T Cells

Arnold Rabson

P089

Cannabinoid Receptors as new targets for HTLV-1 Associated Myelopathy (HAM/TSP) treatment

Afsane Fadaee khoob

P090

Virus-induced RGMa is a key mediator of Neuronal Damage and Therapeutic Target in HAM.

Natsumi Araya

P091

A targeted next-generation sequencing panel to detect ATL driver mutations in suspected pre-malignant clones

Patricia Watber

P092

Role of soluble mediators and T-cell exhaustion in defects in antiviral immunity in premalignancy

Devon Weterings

P093

Bioinformatic analysis identifies key genes associated with clonal expansion of HTLV-1 infected cells

Momoko Usui

P094

Intermediate syndrome related to human T-cell lymphotropic virus type 1 (IS-HTLV-1) – or - Mild Inflammatory Syndrome (MIS): Clinical, laboratory, and radiological parameters definition

Jorge Casseb

P095

Investigation of HAM pathogenesis due to PARP-mediated neuronal death

Masakazu Tanaka

Persistence

P096

The helicase-like transcription factor restricts the infectious cycle of HTLV-1 but interferes with T-cell mediated antiviral cytotoxicity

Aurélie Beauvois



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P097

Dynamics and regulatory mechanisms of HTLV-1 gene expression analyzed by single-cell multiome method using CD4+ T cells from ATL patients

Koki Niimura

P129

The global regulation of deltaretroviruses by CD8+ T cells in a non-lytic manner

Maureen Kidiga

Policy/social impact/stigma

P098

Design and Development of a National HTLV-1 Registry and Associated Disease in Iran

Khalil Kimiafar

P099

Importance of HTLV-1 screening prior to immunocompromising therapies: A case report

Salwa Ahmad

P100

Design and evaluation of patient portal for patients with HTLV1

Khalil Kimiafar

P104

Advancing HTLV public policies in Brazil through engagement with civil and scientific society: a case report

Mayra Gonçalves Aragón

P105

HTLV workshop “Coming out of Invisibility” in the state of Maranhão, Brazil: a case report

Mayra Gonçalves Aragón

Social determinants

P106

Enhancing Health Education: Analysis of the Implementation of the Health Mentors Program for HTLV Patients at a Brazilian Multidisciplinary Center.

Rebeca Mota

Therapy

P107

Developing Specific Inhibitors for HTLV-1 Reverse Transcriptase and Integrase Enzymes

Baratali Mashkani



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P108

pTEFb activators enhance HTLV-1/ Tax transcription superior to the HDACi Romidepsin

Louisa Rasp

P109

Efficacy of L-arginine in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis

Mika Dozono

P110

Identification of small molecule antivirals against HTLV-1 by targeting the hDLG1-Tax-1 protein-protein interaction

Sibusiso Maseko

P111

The BRD4- selective small molecule ZL0580 interferes with protein expression of transcription elongation factor ELL2 and HTLV-1 Tax

Abarna Baheerathan

P112

Tax-targeted dendritic cell vaccine for ATL: TCR repertoire analyses in a long-term survivor

Youko Suehiro

P113

Characterizing immune cell shifts and clonal dynamics in anti-CCR4 monoclonal antibody-treated adult T-cell leukemia-lymphoma (ATL) patients

Osama Hussein

P114

Development of siRNA therapeutics targeting Human T-cell Leukaemia Virus Type-1 (HTLV-1) infection

Tiana Wang

P115

The impact of central nervous system involvement on prognosis and identification of associated risk factors in patients with adult T-cell leukemia-lymphoma: Nagasaki Lymphoma Clinical

Study Group

Junya Makiyama

P118

Organotin-derived compounds as new potential agents to contrast HTLV-1

Beatrice Macchi

P119

Impact of Mogamulizumab-containing Chemotherapy on HBV Reactivation in Patients with adult T-cell leukemia-lymphoma (ATL)

Kisato Nosaka



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

P120

North American adult T-Cell leukemia/lymphoma has frequent mutations in CCR4 and responds in vitro to a small molecule CCR4 antagonist

Eric Liu

P123

Search and Characterization of the Aspartic Peptidase inhibitors of Bovine Leukemia Virus

Martín Fló

Transmission Prevention

P124

Mother-to-child transmission: opposing effects of human skim milk and human milk oligosaccharides on HTLV-1 cell-to-cell transmission

Stefanie Heym

P125

Development of an HTLV-1 mRNA vaccine

Amanda Panfil

P126

Progress towards an HTLV-1 mRNA vaccine for prevention of transmission and disease informed by efforts with HIV-1, SARS-CoV-2 and Hepatitis vaccines.

Damian Purcell

P127

HTLV-1/2 in milk: towards a better understanding of vertical transmission

Beatrice Cockbain